Overview

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
0
Participant gender:
All
Summary
Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
InterMune
Treatments:
Interferon-gamma
Interferons
Criteria
Male or Female, 20-79 years old